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BACKGROUND: No studies to date have demonstrated a clear association with breast cancer risk and dietary exposure to acrylamide.
METHODS: A 217-item food frequency questionnaire was used to estimate dietary acrylamide intake in 33731 women aged 35–69
years from the UK Women’s Cohort Study followed up for a median of 11 years.
RESULTS: In all, 1084 incident breast cancers occurred during follow-up. There was no evidence of an overall association between
acrylamide intake and breast cancer (hazard ratio¼1.08 per 10mgday
 1, 95% CI: 0.98–1.18, Ptrend¼0.1). There was a suggestion of
a possible weak positive association between dietary acrylamide intake and premenopausal breast cancer after adjustment for
potential confounders (hazard ratio¼1.2, 95% CI: 1.0–1.3, Ptrend¼0.008). There was no suggestion of any association for
postmenopausal breast cancer (hazard ratio¼1.0, 95% CI: 0.9–1.1, Ptrend¼0.99).
CONCLUSIONS: There is no evidence of an association between dietary acrylamide intake and breast cancer. A weak association may
exist with premenopausal breast cancer, but requires further investigation.
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Acrylamide is formed principally by the Maillard reaction between
the amino acid asparagine and reducing sugars such as glucose
(Stadler et al, 2002). Until its discovery in high temperature cooked
carbohydrate-rich foods in 2002, it was thought that the main
route of human exposure was occupational or from smoking
(Smith et al, 2001). The finding of significant amounts of
acrylamide in commonly consumed foods, such as potato crisps,
French fries, coffee, biscuits and cold breakfast cereal (Tareke et al,
2002), raised health concerns in light of its classification as a
probable human carcinogen by IARC (IARC Working Group on
the Evaluation of Carcinogenic Risks to Humans, 1994). Animal
studies have demonstrated that exposure to acrylamide causes a
higher incidence of several tumours, including those of the
mammary gland, but at levels of intake much greater than the
equivalent typically observed in humans (Besaratinia and Pfeifer,
2003; Friedman, 2003; Rice, 2005; Spivey, 2010; Tardiff et al, 2010).
As a consequence, several studies have attempted to assess whether
acrylamide exposure through foods increases cancer risk in
humans.
Some evidence has been found of an association between dietary
acrylamide and endometrial and ovarian cancers (Hogervorst et al,
2007), but no studies to date have demonstrated a clear association
with breast cancer risk and dietary exposure to acrylamide (Mucci
et al, 2005; Pelucchi et al, 2006; Hogervorst et al, 2007; Larsson
et al, 2009; Wilson et al, 2009a), apart from one study suggesting a
possible positive association with breast cancer among a subgroup
of postmenopausal never-smokers (Pedersen et al, 2010). In
addition, a recent biomarker study found a possible association
with acrylamide–haemoglobin adduct levels for oestrogen recep-
tor positive postmenopausal breast cancers, though there was no
overall association for postmenopausal breast cancers, and no
investigation of premenopausal breast cancers.
We therefore aimed to investigate the association between
dietary acrylamide intake and all breast cancers in a large
prospective cohort of women. The UK Women’s Cohort Study
(UKWCS) is participating in the NewGeneris consortium investi-
gating dietary exposures to potentially carcinogenic compounds
(Merlo et al, 2009), and is therefore ideally suited to investigating
this question.
MATERIALS AND METHODS
The UKWCS is formed from a sample of 35372 women who
completed a 217-item food frequency questionnaire (FFQ) during
1995–1998 (Cade et al, 2004a). The FFQ was based on the FFQ
used in the UK arm of the European Prospective Investigation into
Cancer study, which had been validated against 16-day weighed
records and biomarkers (Bingham et al, 1997), and adapted for
this population in line with best practise (Cade et al, 2004b)
followed by further validation (Calvert et al, 1997; Buckley et al,
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affluent, well-educated women, and were initially aged between
35 and 69 years. They are generally health conscious with only 11%
current smokers and 58% taking dietary supplements (Cade et al,
2004a). Physical activity levels and self-reported weight, height and
waist and hip circumferences were also collected at baseline.
Ethical approval was obtained from 174 local research ethics
committees as described previously (Cade et al, 2007; Taylor et al,
2007). The cohort was designed to include a wide range of dietary
patterns with similar large numbers of women consuming a
vegetarian type diet, women who ate fish but not meat and meat
eaters, to achieve adequate power while minimising the effects of
measurement error (White et al, 1994; Kaaks and Riboli, 1997;
Schatzkin et al, 2001).
Estimated intakes of acrylamide were calculated for women
participating in the UKWCS using the frequencies of consumption
of 24 food items reported in the FFQ that were potential sources of
dietary acrylamide, broadly grouped into potato chips, crisp
breads, breakfast cereals, pastries and bakery products, coffee,
bread, biscuits and potato crisps. Toast was not included as a
separate item in the FFQ, but was included as bread. Estimated
acrylamide content was based on standard portion sizes (Food
Standards Agency, 2002) and European Union (EU) estimates of
acrylamide content of foods (European Commission Institute for
Reference Materials and Measurements, 2006). The EU database
was set up to permit monitoring of acrylamide levels in food
products throughout the whole EU, which includes the UK.
A recent validation study compared estimated acrylamide intake
based on average acrylamide levels of food items, such as those
available in the EU database, compared with chemically analysed
content (Konings et al, 2010). The correlation between chemically
determined acrylamide content and estimated acrylamide content
was very high, indicating that using single acrylamide values for
individual foods based on average values of several available
samples, such as that reported in the EU database, results in a good
rank ordering of most subjects, despite the large variation of
acrylamide concentrations within single foods. We further adapted
the database for the UK population by using coffee strengths and
portion sizes based on those appropriate for the UK (Food
Standards Agency, 2002), and in addition we assumed that, for
exposure estimates in this population of middle-aged women, any
potato chips consumed were generally broader than the narrower
French fries, and so with a relatively lower acrylamide content. The
FFQ was repeated in a random subsample of 1859 women 5 years
after completion of the first questionnaire. Spearman’s correlation
was 0.61 for total dietary acrylamide intake, with similarly high
values across all dietary sources of acrylamide.
Study participants were registered with the National Health
Service Central Register so that all incident cancer cases and deaths
were notified to the study team. Incident cancers and cause of
death were coded according to the International Classification of
Diseases 9 and 10. An incident breast cancer was taken to be
malignant breast cancer (ICD9 174, ICD10 C50) occurring after
completion of the FFQ. Breast cancer cases’ survival time was
taken as date of completing the FFQ until date of diagnosis. Non-
cases’ survival was taken as being from date of enrolment until
death or end of follow-up (1 January 2008) whichever was the first.
Menopausal status was coded using specific criteria related to
menstrual and obstetric history and age.
Statistical analysis
Cox’s proportional hazards regression was used to explore the
relationship between estimated dietary acrylamide intakes and risk
of breast cancer using Stata version 11 (StataCorp., 2009). Women
were excluded if they had extremely high (46000kcalday
 1)o r
low (o500kcalday
 1) reported total energy intake, as were
women with prevalent breast cancer. Associations were estimated
for premenopausal and postmenopausal women separately and
combined, first as a simple model adjusting for age, smoking status
and amount smoked (model 1), and second as a full model
additionally adjusting for weight, height, physical activity (hours
per day sufficiently vigorous to cause sweating), oral contraceptive
use, hormone replacement therapy use, parity, age at menarche,
alcohol intake (as grams of ethanol per day), energy intake other
than from alcohol, and level of education (model 2). Tests for trend
were based on fitting the linear trend over the continuous measure
of exposure.
To assess sensitivity of results to undiagnosed prevalent breast
cancers at the time the FFQ was completed, analyses were repeated
after excluding any events occurring within 6 months of
completing the FFQ. A further analysis excluding current or ever
smokers was undertaken as exposure to acrylamide through
tobacco smoke inhalation is likely to be a more important source
of exposure than dietary sources alone (Olesen et al, 2008). For this
subgroup there was no need to adjust for smoking habits in the
models. To investigate the sensitivity of results to including all
bread as untoasted, we assumed half of bread was toasted, with
associated higher acrylamide content, and re-ran all analyses.
RESULTS
The median follow up was for 11 years, with 1084 incident breast
cancers recorded. Using information collected at baseline, 15951
women were classified as being premenopausal and 17779
postmenopausal. Demographic and clinical characteristics of the
study participants are shown in Table 1 according to fifth of
acrylamide intake. The women with the highest dietary acrylamide
intakes were slightly younger, with higher body mass index, less
physically active, less educated, more likely to have children, have
a higher total energy intake, have a lower alcohol intake, but more
likely to smoke.
Median dietary acrylamide intake was 15mgday
 1 (0.23mgkg
 1
day
 1), with an inter-quartile range of 10–21mgday
 1 (0.15–
0.33mgkg
 1day
 1). Only 316 out of 33061 (1%) of women
consumed more than 50mgday
 1 of dietary acrylamide. Only 99
out of 33061 (0.3%) of participants consumed in excess of
1mgkg
 1day
 1, a threshold of intake cited by the World Health
Organization in risk assessment models (Joint Food and
Agriculture Organization of the United Nations/World Health
Organization consultation on health implications of acrylamide in
food, 2002), and still fewer exceed other estimates of tolerable daily
intake (Tardiff et al, 2010). The sources with greatest contribution
to total dietary acrylamide intake in these middle-aged women in
the United Kingdom were potato chips (28% of intake), bakery
goods (17%), potato crisps (14%), bread (10%), biscuits (9%) and
coffee (8%).
Overall, there was little evidence of an association between
dietary acrylamide intake and breast cancer when premenopausal
and postmenopausal cancers were combined (hazard ratio¼1.08
per 10mgday
 1, 95% CI: 0.98–1.18, Ptrend¼0.1) (Table 2).
However, there was evidence of a positive dose-response associa-
tion between dietary acrylamide intake and premenopausal breast
cancer after adjustment for potential confounders. Women in the
highest fifth of dietary acrylamide intake had B50% higher risk of
subsequent breast cancer than those in the lowest fifth (hazard
ratio¼1.47, 95% CI: 0.96–2.27) with associated risk increasing
by B20% with every 10mgday
 1 increase in acrylamide intake
(hazard ratio¼1.18, 95% CI: 1.05–1.34, Ptrend¼0.008). However,
there was no such association for postmenopausal breast cancer
(hazard ratio¼1.00, 95% CI: 0.88–1.14, Ptrend¼0.99), with similar
numbers of premenopausal and postmenopausal women offering
similar power for each comparison.
These results were unchanged by excluding women with breast
cancers diagnosed within 6 months of completing the FFQ. When
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who had never smoked, the associations between dietary
acrylamide and breast cancer were less apparent, though power
was much reduced (Table 3). If half of all recorded bread intake
were as toast, this would increase the median acrylamide intake
to 20mgday
 1 (inter-quartile range 14–27mgday
 1)o r
0.31mgkg
 1day
 1 (inter-quartile range 0.21–0.43mgkg
 1day
 1).
However, dose-response trends were very much the same as
before.
DISCUSSION
In our large UK cohort, we have shown no association between
dietary acrylamide intake and increased risk of breast cancer,
either overall or for postmenopausal breast cancer, for modest
intakes consumed as part of a usual diet (o50mgday
 1). However,
there was some evidence for a positive association with
premenopausal breast cancer. There was a weak dose-response
relationship, but the association was particularly apparent in the
highest fifth of dietary intake (423mgday
 1).
Given that smoking is not a risk factor for breast cancer, and
that smokers have substantially higher levels of haemoglobin
adducts of acrylamide and glycidamide than non-smokers
(Hagmar et al, 2005; Bjellaas et al, 2007), much higher than that
associated with dietary intake, any association between dietary
intake and breast cancer is surprising. Given also that the
acrylamide content of tobacco outweighs any that of any dietary
intake, it was also important to repeat the analyses amongst a
subgroup of never-smokers.
Table 1 Demographic and clinical characteristics of women in the UKWCS by fifth of intake of acrylamide
Acrylamide intake
Fifth 12345
Mean (lgday
 1) 6 11 15 20 32
Range (lgday
 1) 0–9 9–13 13–17 17–23 23–150
Mean age (years) (s.d.) 52.8 (9.2) 52.7 (9.1) 52.5 (9.3) 51.6 (9.3) 51.4 (9.5)
Mean BMI (kgm
 2) (s.d.) 24.0 (4.2) 24.5 (4.4) 24.4 (4.1) 24.6 (4.6) 24.8 (4.5)
Mean physical activity (hours per day) (s.d.) 0.3 (0.5) 0.3 (0.5) 0.3 (0.5) 0.2 (0.4) 0.2 (0.5)
Mean age at menarche (years) (s.d.) 12.8 (1.7) 12.8 (1.6) 12.8 (1.6) 12.8 (1.6) 12.9 (1.6)
Current HRT use (%) 1336 (20%) 1386 (21%) 1348 (20%) 1239 (19%) 1206 (18%)
Current OCP use (%) 251 (4%) 232 (3%) 278 (4%) 264 (4%) 266 (4%)
Nulliparous (%) 1954 (29%) 1614 (24%) 1394 (21%) 1346 (20%) 1240 (18%)
Postmenopause (%) 3776 (56%) 3716 (55%) 3620 (54%) 3360 (50%) 3300 (49%)
Incident breast cancer (%) 220 (3%) 213 (3%) 219 (3%) 211 (3%) 218 (3%)
Mean total energy intake (MJ) (s.d.) 8.0 (2.4) 8.9 (2.4) 9.6 (2.4) 10.4 (2.6) 12.1 (3.3)
Mean ethanol intake (gday
 1) (s.d.) 9.0 (11.4) 9.1 (10.5) 8.7 (10.6) 8.5 (10.1) 8.0 (10.1)
Current smoker (%) 684 (11%) 682 (10%) 710 (11%) 718 (11%) 846 (13%)
No education 4 14 years (%) 840 (14%) 951 (15%) 1038 (17%) 1076 (17%) 1291 (21%)
Abbreviations: BMI¼body mass index; HRT¼hormone replacement therapy; OCP¼oral contraceptive pill; UKWCS¼UK Women’s Cohort Study.
Table 2 Hazard ratios of pre- and post-menopausal breast cancer according to acrylamide intake for all participants
Model 1
a Model 2
b
Fifth of acrylamide intake Range (lgday
 1) Cases/Total HR 95% CI Ptrend
c HR 95% CI Ptrend
c
All breast cancers
1 0–9 220/6747 1.00 — 1.00 —
2 9–13 213/6748 0.92 (0.74, 1.13) 1.06 (0.83, 1.35)
3 13–17 219/6747 0.90 (0.73, 1.11) 1.05 (0.82, 1.34)
4 17–23 211/6748 0.92 (0.75, 1.14) 1.12 (0.87, 1.45)
5 23–150 218/6748 0.97 (0.79, 1.19) 1.16 (0.88, 1.52)
Trend (per 10mgday
 1) 0.99 (0.92, 1.06) 0.7 1.08 (0.98, 1.18) 0.1
Premenopausal
1 0–9 73/2956 1.00 — 1.00 —
2 9–13 85/3032 1.03 (0.7, 1.5) 1.06 (0.71, 1.59)
3 13–17 88/3127 1.01 (0.7, 1.4) 1.15 (0.77, 1.71)
4 17–23 90/3388 0.95 (0.7, 1.3) 1.15 (0.76, 1.73)
5 23–150 102/3448 1.20 (0.9, 1.7) 1.47 (0.96, 2.27)
Trend (per 10mgday
 1) 1.06 (0.96, 1.17) 0.2 1.18 (1.05, 1.34) 0.008
Postmenopausal
1 0–9 135/3776 1.00 — 1.00 —
2 9–13 128/3716 0.96 (0.7, 1.2) 1.06 (0.78, 1.44)
3 13–17 131/3620 0.95 (0.7, 1.2) 1.00 (0.73, 1.38)
4 17–23 121/3360 1.03 (0.8, 1.3) 1.14 (0.82, 1.58)
5 23–150 116/3300 0.97 (0.7, 1.3) 0.97 (0.68, 1.39)
Trend (per 10mgday
 1) 0.98 (0.90, 1.07) 0.7 1.00 (0.88, 1.14) 0.99
Abbreviations: CI¼confidence interval; HR¼hazard ratio.
aModel 1 is adjusted for age.
bModel 2 is also adjusted for smoking status and amount smoked weight, height, physical
activity (hours per day sufficiently vigorous to cause sweating), oral contraceptive use, hormone replacement therapy use, parity, age at menarche, alcohol intake (as grams of
ethanol per day), energy intake other than from alcohol, and level of education.
cP-value for trend is based on fitting the linear trend over the continuous exposure.
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premenopausal women, who had never smoked. It is possible that
the lack of a clear association amongst the never-smokers could be
explained by insufficient power to detect increased risk, as this
subgroup comprises just a quarter of the cohort. However, the
overall number of cases of breast cancer reported in our cohort are
comparable to those in other major studies, such as the Nurses’
Health Study II (Wilson et al, 2009a), which found no associations
between intakes of acrylamide, or foods potentially high in
acrylamide, and invasive breast cancer.
The FFQ used in our cohort is similar to that used in the
European Prospective Investigation of Cancer (Riboli and Kaaks,
1997) and follows recommendations for good design (Cade et al,
2004b). However, no distinction was made between bread and
toasted bread, which would have higher acrylamide content. When
the robustness of results was assessed by assuming a proportion of
bread was toasted, conclusions were unchanged.
Our average intakes were at the lower end of those previously
reported from other populations (Swiss Federal Office of Public
Health, 2002; Dybing and Sanner, 2003; Svensson et al, 2003;
US Food and Drug Administration, 2006; Larsson et al, 2009;
Wilson et al, 2009b). Partly this is an artefact of presenting the
more appropriate median intake, which is generally lower than the
mean (Dybing et al, 2005), and partly underestimation caused by
grouping bread and toast together. However, we believe these
lower intakes also reflect the dietary habits of our middle-aged
female UK population who, at the time of completing the FFQ,
consumed relatively fewer potato chips and crisps, generally
preferred tea rather than coffee, and consumed weaker coffee than
some other countries.
Our intakes are closer to those found in the US, Switzerland and
the Netherlands, than to those found in Scandinavia. For example,
the proportion of acrylamide estimated to be from coffee in our
population (8%) is in keeping with figures from the Netherlands
and US (Mucci and Wilson, 2008), but very different from the 39%
reported in Sweden. The UKWCS participants generally have a
health conscious outlook with relatively low smoking rates and low
body mass index (Cade et al, 2004a). It is therefore possible that
less healthy dietary patterns were under-represented in our cohort.
This may also have contributed to the relatively low daily intake of
acrylamide in the UKWCS compared with other studies.
Even in our relatively health-conscious cohort of middle-aged
women, the main sources of acrylamide were chips and crisps. It is
therefore possible that any measure of dietary acrylamide intake
may be a proxy for poor diet, which could predict breast cancer.
This in turn may be predictive of increased risk of breast cancer
through other dietary risk factors such as higher fat or processed
meat intakes (Bingham et al, 2003; Cade et al, 2007; Taylor et al,
2007).
As this is a prospective study, recall bias is unlikely. However, it
is possible that current estimates of acrylamide content in food are
incomplete, which may have lead to some misclassification of
exposure categories. In addition, estimates of acrylamide exposure
were based on the responses to one FFQ administered at
recruitment into the cohort. As the consumption of foods thought
to be contaminated with acrylamide may have changed over time,
it is possible that our estimates of exposure might have been
improved with repeated dietary assessments. The range of
acrylamide levels reported for specific products, with different
methods of preparation, is wide, and even within brands
considerable variation occurs between different batches (European
Food Safety Authority, 2010). As the FFQ does not request brand-
specific information, and individuals do not necessarily remain
loyal to one brand, this variation could not be accounted for in the
exposure calculations. In particular, the acrylamide content of
coffee will differ by brand and strength of coffee consumed
(Bagdonaite et al, 2008). This choice varies considerably between
individuals, and across different countries. However, studies have
shown that it is possible for FFQs to estimate dietary acrylamide
intake well (Dybing et al, 2005; Brantsaeter et al, 2008).
Table 4 briefly summaries the results from some existing studies
of dietary acrylamide and breast cancer. The majority of studies,
like ours, found no evidence of an association between dietary
acrylamide intake and incident breast cancer, at least within the
Table 3 Hazard ratios of pre- and post-menopausal breast cancer according to acrylamide intake for women who have never smoked
Model 1
a Model 2
b
Fifth of acrylamide intake Range (lgday
 1) Cases/Total HR 95% CI Ptrend
c HR 95% CI Ptrend
c
All breast cancers
1 0–9 128/3584 1.00 — 1.00 —
2 9–13 114/3745 0.78 (0.60, 1.03) 0.87 (0.63, 1.20)
3 13–17 130/3847 0.82 (0.63, 1.07) 0.95 (0.69, 1.30)
4 17–23 120/3885 0.79 (0.60, 1.03) 0.96 (0.69, 1.34)
5 23–150 115/3841 0.82 (0.62, 1.07) 0.98 (0.69, 1.40)
Trend (per 10mgday
 1) 0.94 (0.85, 1.04) 0.2 1.06 (0.93, 1.21) 0.4
Premenopausal
1 0–9 45/1604 1.00 — 1.00 —
2 9–13 38/1709 0.73 (0.45, 1.19) 0.68 (0.39, 1.20)
3 13–17 59/1805 1.04 (0.68, 1.61) 1.12 (0.69, 1.83)
4 17–23 54/1990 0.80 (0.51, 1.25) 0.98 (0.59, 1.62)
5 23–150 57/2024 1.00 (0.65, 1.54) 1.17 (0.69, 2.00)
Trend (per 10mgday
 1) 1.01 (0.88, 1.15) 0.9 1.13 (0.95, 1.33) 0.2
Postmenopausal
1 0–9 76/1972 1.00 — 1.00 —
2 9–13 76/2036 0.89 (0.64, 1.26) 0.98 (0.66, 1.46)
3 13–17 71/2042 0.79 (0.56, 1.13) 0.83 (0.54, 1.26)
4 17–23 66/1895 0.89 (0.63, 1.25) 0.99 (0.64, 1.53)
5 23–150 58/1817 0.81 (0.57, 1.16) 0.86 (0.53, 1.37)
Trend (per 10mgday
 1) 0.95 (0.83, 1.08) 0.4 1.01 (0.83, 1.24) 0.9
Abbreviations: CI¼confidence interval; HR¼hazard ratio.
aModel 1 is adjusted for age.
bModel 2 is also adjusted for smoking status and amount smoked weight, height, physical
activity (hours per day sufficiently vigorous to cause sweating), oral contraceptive use, hormone replacement therapy use, parity, age at menarche, alcohol intake (as grams of
ethanol per day), energy intake other than from alcohol, and level of education.
cP-value for trend is based on fitting the linear trend over the continuous exposure.
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indications of a positive association between dietary acrylamide
intake and a subgroup of hormone receptor-positive breast cancers
in postmenopausal women, who have never smoked (Hogervorst
et al, 2007; Pedersen et al, 2010), and recognised that further
studies were required to confirm or refute this. However, there is
other evidence that acrylamide may interfere with hormone
systems (Hogervorst et al, 2010). A weakness of our study was
that we did not have information on hormone receptor status and
so we were unable to selectively report results by tumour receptor
positivity.
The strongest suggestion of a positive association comes from a
large prospective cohort (Olesen et al, 2008), where the association
between breast cancer and biomarkers for acrylamide exposure
was assessed using haemoglobin adduct levels, as well as
glycidamide, which is the genotoxic metabolite of acrylamide.
After adjustment for smoking behaviour in their nested case–
control study, a positive association was seen between acrylamide
and haemoglobin adduct levels and oestrogen receptor positive
breast cancer. Our study takes this further and relates breast
cancer directly to the original dietary consumption that may
contribute to the adduct levels and metabolite concentrations.
A recent cross-sectional analysis of individuals found higher
biomarker values of acrylamide in the United Kingdom than in
other European countries (Vesper et al, 2008), suggesting that this
may be of particular importance in the United Kingdom, and a
possible explanation for any differences between our results and
those from other countries.
There is some mechanistic evidence to support this epidemio-
logical evidence. In animal studies, acrylamide is causally
associated with mammary tumour development (Johnson et al,
1986; Friedman et al, 1995; Rice, 2005; Wilson et al, 2009a), but to
date there has been less evidence that acrylamide consumption at
levels typically observed in normal diets is related to human breast
cancer risk. The typical acrylamide intake of women in our study is
substantially lower than the dose levels that have been found to
cause effects in these animal studies.
Given the widespread presence of acrylamide in food and the
relatively common nature of breast cancer, even a small
association between the two would have important public health
implications. In this first UK study, no overall association between
dietary acrylamide intake and breast cancer risk was found, though
a weak positive association was observed among premenopausal
breast cancers, but further investigation is needed.
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